methotrexate has been researched along with Metabolic Syndrome in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.34) | 29.6817 |
| 2010's | 22 (75.86) | 24.3611 |
| 2020's | 4 (13.79) | 2.80 |
| Authors | Studies |
|---|---|
| Beburov, MY; Brovkin, AN; Dyachenko, IA; Frolova, AA; Goryacheva, NA; Kaluzhsky, VE; Kazakov, VA; Murashev, AN; Pakhomova, IA; Rasskazova, EA; Sadovnikova, ES; Shaykhutdinova, ER; Slashcheva, GA; Tukhovskaya, EA | 1 |
| Chonprasertsuk, S; Jatuworapruk, K; Lertnawapan, R; Siramolpiwat, S | 1 |
| Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Farley Prater, EA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Wong, EB; Wu, JJ | 1 |
| Bellinato, F; Bruni, M; De Angelis, G; Girolomoni, G; Gisondi, P | 1 |
| Alazawi, W; Cho, W; Shetty, A; Syn, WK | 1 |
| Fassio, A; Gatti, D; Giollo, A; Girolomoni, G; Gisondi, P; Idolazzi, L; Rossini, M; Viapiana, O; Zamboni, M | 1 |
| Bertrand, O; Butman, S; Clearfield, M; Everett, BM; Glynn, RJ; Goldhaber, SZ; Gupta, M; Hasan, A; Iturriaga, E; Johnston, J; Le May, M; Libby, P; MacFadyen, JG; Mam, V; Ofori, C; Paynter, NP; Pradhan, A; Ridker, PM; Rosenberg, Y; Saklayen, M; Seagle, R; Singh, N; Solomon, DH; Tsigoulis, M; Verma, S; Zaharris, E | 1 |
| Chonprasertsuk, S; Lertnawapan, R; Siramolpiwat, S | 1 |
| Abdelli, N; Ben Lagha, I; Dhaoui, MR; Jaber, K; Mrabet, A; Rabhi, F; Slimane, BB | 1 |
| Clearfield, M; Everett, BM; Glynn, RJ; Gupta, M; Hasan, AA; Libby, P; Macfadyen, J; Paynter, N; Pradhan, AD; Ridker, PM; Solomon, DH; Zaharris, E | 1 |
| Calhau, C; Cunha, A; Faria, A; Keating, E; Marques, C; Meireles, M; Monteiro, R; Pestana, D; Teixeira, D | 1 |
| Atteno, M; Caso, F; Caso, P; Costa, L; Darda, MA; Del Puente, A; Fiocco, U; Ortolan, A; Punzi, L; Ramonda, R; Scarpa, R | 1 |
| Pais, R; Ratziu, V; Rusu, E | 1 |
| Abourazzak, FE; Harzy, T; Mansouri, S; Najdi, A; Nejjari, C; Tahiri, L | 1 |
| Aithal, GP; Dawwas, MF | 1 |
| Kirby, B; Ryan, C | 1 |
| Philipsen, P; Skiveren, J; Therming, G | 1 |
| Biterman, H; Cohen, AD; Feldhamer, I; Freud, T; Greenberg-Dotan, S; Harman-Boehm, I; Moser, H; Polishchuk, I; Shalom, G; Zisman, D | 1 |
| Mahmud, TH; Rasheed, A; Wagan, AA; Zafar, ZA | 1 |
| Kalińska-Bienias, A; Kowalewski, C; Lesniewska, A; Schwartz, R; Wozniak, K | 1 |
| Berman, E; Cohen, AD; Eran, CB; Feldhamer, I; Freud, T; Hodak, E; Oren, S; Pavlovsky, L; Shalom, G; Ziv, M | 1 |
| Douglas, KM; John, H; Kitas, GD; Panoulas, VF; Toms, TE | 1 |
| Dijkmans, BA; Nurmohamed, MT; Raterman, HG; Voskuyl, AE | 1 |
| Ferrazzi, A; Girolomoni, G; Gisondi, P | 1 |
| Akhlaghi, S; Ferns, GA; Ghayour-Mobarhan, M; Goshayeshi, L; Hatef, MR; Mirfeizi, Z; Rezaieyazdi, Z; Sahebari, M; Sahebkar, A | 1 |
| Kikuchi, N; Kuhara, M; Saiki, O; Shiraishi, S; Uda, H | 1 |
| Menter, A; Ryan, C | 1 |
| Larrain, S; Rinella, ME | 1 |
| Beutner, KR; Bhushan, R; Elmets, CA; Feldman, SR; Gordon, KB; Gottlieb, A; Koo, JY; Korman, NJ; Lebwohl, M; Leonardi, CL; Menter, A; Van Voorhees, AS | 1 |
6 review(s) available for methotrexate and Metabolic Syndrome
| Article | Year |
|---|---|
Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease.
Topics: Antirheumatic Agents; Chemical and Drug Induced Liver Injury; Dermatologic Agents; Diabetes Mellitus; Humans; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Obesity; Risk Factors | 2017 |
The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease.
Topics: Acetaminophen; Anesthetics; Animals; Chemical and Drug Induced Liver Injury; Fatty Liver; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Insulin Resistance; Male; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Obesity; Prevalence; Risk Factors; Trans-Activators; Viral Regulatory and Accessory Proteins | 2014 |
Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.
Topics: Acitretin; Adipokines; Alcoholism; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Comorbidity; Cyclosporine; Dermatologic Agents; Diabetes Mellitus; Fumarates; Humans; Immunosuppressive Agents; Inflammation; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; Risk Factors; Smoking; Tumor Necrosis Factor-alpha; Ustekinumab | 2015 |
Metabolic comorbidities and psoriasis.
Topics: Arthritis, Psoriatic; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Liver; Humans; Hypertriglyceridemia; Immunosuppressive Agents; Insulin Resistance; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Obesity; Psoriasis; Risk Factors | 2010 |
Psoriasis and cardiovascular disorders.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Cardiotonic Agents; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Humans; Inflammation; Interleukin-12 Subunit p40; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Smoking; Tumor Necrosis Factor-alpha; Ustekinumab | 2012 |
A myriad of pathways to NASH.
Topics: Amiodarone; Anti-Retroviral Agents; Bacterial Infections; Cannabis; Diet; Fatty Liver; Genetic Diseases, Inborn; Glucocorticoids; Humans; Hypothyroidism; Insulin Resistance; Intestinal Diseases; Lipid Metabolism; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Occupational Diseases; Perhexiline | 2012 |
3 trial(s) available for methotrexate and Metabolic Syndrome
| Article | Year |
|---|---|
Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome.
Topics: Antibodies, Monoclonal, Humanized; Female; Humans; Male; Metabolic Syndrome; Methotrexate; Psoriasis; Severity of Illness Index; Treatment Outcome | 2020 |
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Confidence Intervals; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Interleukin-1beta; Interleukin-6; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Statistics, Nonparametric; Stroke; Transaminases | 2019 |
Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.
Topics: Algorithms; Anti-Inflammatory Agents; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Inflammation; Metabolic Syndrome; Methotrexate; Myocardial Infarction; Research Design | 2013 |
20 other study(ies) available for methotrexate and Metabolic Syndrome
| Article | Year |
|---|---|
AICAR Improves Outcomes of Metabolic Syndrome and Type 2 Diabetes Induced by High-Fat Diet in C57Bl/6 Male Mice.
Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Diabetes Mellitus, Type 2; Diet, High-Fat; Male; Metabolic Syndrome; Methotrexate; Mice; Mice, Inbred C57BL; Ribonucleosides | 2022 |
Correlation between Cumulative Methotrexate Dose, Metabolic Syndrome and Hepatic Fibrosis Detected by FibroScan in Rheumatoid Arthritis Patients.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Elasticity Imaging Techniques; Humans; Insulin Resistance; Liver Cirrhosis; Metabolic Syndrome; Methotrexate | 2023 |
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
Topics: Adolescent; Adrenal Cortex Hormones; Anthralin; Biological Products; Calcineurin Inhibitors; Cardiovascular Diseases; Child; Child, Preschool; Coal Tar; Comorbidity; Cyclosporine; Dermatologic Agents; Dyslipidemias; Evidence-Based Medicine; Humans; Infant; Infant, Newborn; Inflammatory Bowel Diseases; Insulin Resistance; Mental Health; Metabolic Syndrome; Methotrexate; Nicotinic Acids; Obesity; Photochemotherapy; Psoriasis; Retinoids | 2020 |
Effects of secukinumab on serum adipocytokines: preliminary data.
Topics: Adipokines; Adipose Tissue, White; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Drug Therapy, Combination; Female; Humans; Interleukin-17; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Prospective Studies; Sex Factors | 2017 |
Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate.
Topics: Adult; Aged; Alanine Transaminase; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Elasticity Imaging Techniques; Fatty Liver; Female; Humans; Liver Cirrhosis; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Predictive Value of Tests; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2019 |
Psoriasis and liver fibrosis: an investigation using transient elastography in Tunisian patients with psoriasis.
Topics: Adult; Comorbidity; Dose-Response Relationship, Drug; Elasticity Imaging Techniques; Female; Humans; Liver; Liver Cirrhosis; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Prevalence; Psoriasis; Severity of Illness Index; Tunisia | 2019 |
Methotrexate enhances 3T3-L1 adipocytes hypertrophy.
Topics: 3T3 Cells; Adipocytes; Adipogenesis; Animals; Arthritis, Rheumatoid; Biological Transport; Cell Differentiation; Cell Line; Cell Proliferation; Cell Survival; Folic Acid Antagonists; Glucose; Insulin; Lipid Metabolism; Metabolic Syndrome; Methotrexate; Mice; Obesity | 2013 |
Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.
Topics: Adalimumab; Adipocytes; Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Apoptosis; Arthritis, Psoriatic; Biological Products; Cohort Studies; Comorbidity; Etanercept; Female; Humans; Immunoglobulin G; Inflammation; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Receptors, Tumor Necrosis Factor; Retrospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Prevalence of metabolic syndrome in patients with rheumatoid arthritis in Morocco: a cross-sectional study of 179 cases.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Comorbidity; Cross-Sectional Studies; Female; Humans; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Morocco; Prevalence; Risk Factors | 2014 |
End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.
Topics: Aged; Body Mass Index; Cholangitis, Sclerosing; Diabetes Mellitus; End Stage Liver Disease; Female; Humans; Immunosuppressive Agents; Liver Diseases, Alcoholic; Liver Transplantation; Logistic Models; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; Risk Factors; United States | 2014 |
Patients with psoriasis have insufficient knowledge of their risk of atherothrombotic disease and metabolic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Psoriatic; Atherosclerosis; Depressive Disorder; Diabetes Mellitus; Female; Health Knowledge, Attitudes, Practice; Humans; Hypertension; Immunosuppressive Agents; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Obesity; Patient Education as Topic; Psoriasis; Risk Factors; Thrombosis; Young Adult | 2015 |
Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis.
Topics: Acitretin; Administration, Oral; Adult; Age Factors; Aged; Arthritis, Psoriatic; Databases, Factual; Dermatologic Agents; Drug Prescriptions; Female; Folic Acid; Humans; Israel; Kaplan-Meier Estimate; Keratolytic Agents; Male; Medication Adherence; Metabolic Syndrome; Methotrexate; Middle Aged; Psoriasis | 2015 |
Frequency of metabolic syndrome in Pakistani cohort of patients with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Female; Humans; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Pakistan; Young Adult | 2016 |
Development of bullous pemphigoid in a patient with psoriasis and metabolic syndrome.
Topics: Adult; Autoantibodies; Dose-Response Relationship, Drug; Dystonin; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Metabolic Syndrome; Methotrexate; Pemphigoid, Bullous; Psoriasis; Treatment Outcome | 2016 |
Biologic drug survival in Israeli psoriasis patients.
Topics: Acitretin; Adalimumab; Adult; Databases, Factual; Dermatologic Agents; Drug Substitution; Drug Therapy, Combination; Drug Tolerance; Etanercept; Female; Humans; Immunosuppressive Agents; Infliximab; Interleukin-12 Receptor beta 1 Subunit; Israel; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Psoriasis; Time Factors; Tumor Necrosis Factor-alpha; Ustekinumab | 2017 |
Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Female; Humans; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Prevalence | 2009 |
Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Metabolic Syndrome; Methotrexate; Prevalence | 2009 |
Investigation of the association between metabolic syndrome and disease activity in rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Iran; Logistic Models; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Prednisolone; Prevalence; Risk Assessment | 2011 |
Evaluation of lasting high levels of CRP among the patients with metabolic syndrome.
Topics: Adipose Tissue; Biomarkers; Body Mass Index; C-Reactive Protein; Female; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Male; Metabolic Syndrome; Methotrexate | 2012 |
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Topics: Acitretin; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biological Products; Cardiovascular Diseases; Cyclosporine; Depression; Etanercept; Humans; Immunoglobulin G; Interleukin-12; Interleukin-23; Lymphoma; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Smoking; Tumor Necrosis Factor-alpha | 2008 |